Additionally, Prevent Blindness is participating in the first World Geographic Atrophy Day on Tuesday, Dec. 5, 2023. The goal of the new initiative is to empower the voices of the global GA community, and provide education, advocacy, and support. World Geographic Atrophy Day is a partnership between
BrightFocus Foundation,
Fighting Blindness Canada,
Macular Society, and Prevent Blindness, and is supported with funding provided by Apellis Pharmaceuticals, Inc.
As part of GA Week at Prevent Blindness, a new episode in the Prevent Blindness
Focus on Eye Health Expert Series, “Advancements in Treatments for Geographic Atrophy,” will be available featuring Rajeev S. Ramchandran, MD, MBA, Associate Professor of Ophthalmology, Flaum Eye Institute,
University of Rochester Medical Center. Dr. Ramchandran also serves as the volunteer chairperson of the Prevent Blindness Scientific Committee, and is a member of its Board of Directors.
GA can lead to progressive and permanent vision loss. Patients with GA in one eye are more likely to develop it in the other eye. There may be no symptoms in the early stages until the disease progresses or affects both eyes. Vision changes due to GA may include some of the following symptoms:
- Difficulty seeing in the center of vision
- Numbers or letters disappearing or missing when reading
- A dim or dark spot in central or near central (side) vision
- Trouble seeing in dim light
- Needing extra light to read
- Dull or washed-out colors
- Vision not as clear or sharp
“The good news is that promising new treatments for GA are now available, with additional options in development,” said Jeff Todd, president and CEO of Prevent Blindness. “By working closely with their eye doctors, people with GA have hope to preserve their vision from the damaging effects of GA.”
For GA and/or AMD patients and their care partners, Prevent Blindness also offers the free resource,
Living Well With Low Vision. This program provides a variety of free directories, a library of self-help guides, downloadable apps including “GuideME for AMD,” access to clinical trial research, and recentAMD research news.